Chang Che-Wei, Chien Chu-Chun, Juan Yung-Shun, Chueh Kuang-Shun
Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Urol Case Rep. 2020 Sep 9;34:101407. doi: 10.1016/j.eucr.2020.101407. eCollection 2021 Jan.
Angiosarcoma (AS) is a rare aggressive tumor originating from endothelial cells. We reported a 66-year-old female with primary renal angiosarcoma (PRA) who presented as urothelial carcinoma with hematuria and dysuria. Based on ureterorenoscopic tumor biopsy, the initial diagnosis suggested low-grade non-invasive urothelial carcinoma. However, the specimen retrieved from nephroureterectomy confirmed the diagnosis of primary renal angiosarcoma. Primary renal angiosarcoma could uncommonly present as urothelial carcinoma in renal pelvis. Surgical resection remains to be the most effective therapy but there is no consensus about adjuvant therapies. The overall prognosis of primary renal angiosarcoma is dismal.
血管肉瘤（AS）是一种起源于内皮细胞的罕见侵袭性肿瘤。我们报告了一名66岁的原发性肾血管肉瘤（PRA）女性患者，其表现为血尿和排尿困难的尿路上皮癌。根据输尿管肾镜肿瘤活检，初步诊断为低级别非侵袭性尿路上皮癌。然而，肾输尿管切除术获取的标本确诊为原发性肾血管肉瘤。原发性肾血管肉瘤很少表现为肾盂尿路上皮癌。手术切除仍然是最有效的治疗方法，但关于辅助治疗尚无共识。原发性肾血管肉瘤的总体预后不佳。
